(Q30389282)

21 June 2017

title

Challenges in the treatment of HIV and HCV coinfection (English)

1 reference

21 June 2017

0 references

1

Hendrik Streeck

1 reference

21 June 2017

2

Jürgen K Rockstroh

1 reference

21 June 2017

language of work or name

1 reference

1 September 2006

1 reference

Expert Review of Clinical Immunology

21 June 2017

published in

1 reference

21 June 2017

volume

2

1 reference

21 June 2017

issue

5

1 reference

21 June 2017

page(s)

811-822

1 reference

Influence of hepatitis C virus infection on HIV-1 disease progression and response to highly active antiretroviral therapy

21 June 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.5.811

Hepatitis C Virus prevalence among patients infected with Human Immunodeficiency Virus: a cross-sectional analysis of the US adult AIDS Clinical Trials Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.5.811

Prevalence and determinants of antibodies to hepatitis C virus and markers for hepatitis B virus infection in patients with HIV infection in Aquitaine. Groupe d'Epidémiologie Clinique du SIDA en Aquitaine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.5.811

Increased numbers of acute hepatitis C infections in HIV positive homosexual men; is sexual transmission feeding the increase?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.5.811

Mother-to-infant transmission of hepatitis C virus. Lombardy Study Group on Vertical HCV Transmission

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.5.811

Human immunodeficiency virus infection modifies the natural history of chronic parenterally-acquired hepatitis C with an unusually rapid progression to cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.5.811

Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.5.811

The progression of HCV-associated liver disease in a cohort of haemophilic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.5.811

Intrahepatic HCV levels in chronic HCV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.5.811

Hepatitis C virus infection-related morbidity and mortality among patients with human immunodeficiency virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.5.811

Mortality due to hepatitis C-related liver disease in HIV-infected patients in France (Mortavic 2001 study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.5.811

Influence of human immunodeficiency virus type 1 infection on the natural course of chronic parenterally acquired hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.5.811

HIV coinfection shortens the survival of patients with hepatitis C virus-related decompensated cirrhosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.5.811

Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.5.811

Hepatitis C virus load is associated with human immunodeficiency virus type 1 disease progression in hemophiliacs

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.5.811

Coinfection of hepatitis C virus with human immunodeficiency virus and progression to AIDS. Italian Seroconversion Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.5.811

Hepatitis C in the HIV (human immunodeficiency virus) Atlanta V.A. (Veterans Affairs Medical Center) Cohort Study (HAVACS): the effect of coinfection on survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.5.811

Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.5.811

Hepatitis C virus co-infection is a negative prognostic factor for clinical evolution in human immunodeficiency virus-positive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.5.811

CD4 T-lymphocyte recovery in individuals with advanced HIV-1 infection receiving potent antiretroviral therapy for 4 years: the Swiss HIV Cohort Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.5.811

Influence of viral hepatitis on HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.5.811

Care of patients with hepatitis C and HIV co-infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.5.811

Chronic Hepatitis C Virus Infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.5.811

Intrahepatic HCV RNA loads in 37 HIV-HCV co-infected patients with controlled HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.5.811

BHIVA guidelines on HIV and chronic hepatitis: coinfection with HIV and hepatitis C virus infection (2005).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.5.811

Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.5.811

Hepatotoxicity in HIV-1-infected patients receiving nevirapine-containing antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.5.811

Liver fibrosis progression is related to CD4 cell depletion in patients coinfected with hepatitis C virus and human immunodeficiency virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.5.811

Slower fibrosis progression in HIV/HCV-coinfected patients with successful HIV suppression using antiretroviral therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.5.811

Time on antiretroviral therapy is a protective factor for liver fibrosis in HIV and hepatitis C virus (HCV) co-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.5.811

The effect of antiretroviral therapy on liver disease among adults with HIV and hepatitis C coinfection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.5.811

Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C virus coinfection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.5.811

Survival in patients with HIV infection and viral hepatitis B or C: a cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.5.811

Special considerations in the initiation and management of antiretroviral therapy in individuals coinfected with HIV and hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.5.811

Acute hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.5.811

Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.5.811

Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.5.811

Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.5.811

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for treatment of HIV/HCV co-infected patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.5.811

Ribavirin antagonizes the effect of azidothymidine on HIV replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.5.811

Effect of ribavirin on intracellular and plasma pharmacokinetics of nucleoside reverse transcriptase inhibitors in patients with human immunodeficiency virus-hepatitis C virus coinfection: results of a randomized clinical study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.5.811

Pegylated IFN-alpha2b plus ribavirin as therapy for chronic hepatitis C in HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.5.811

Pegylated interferon alpha-2b plus ribavirin for the treatment of chronic hepatitis C in HIV-coinfected patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.5.811

Extending combination therapy with peginterferon alfa-2b plus ribavirin for genotype 1 chronic hepatitis C late responders: A report of 9 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.5.811

Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.5.811

Short statement of the first European Consensus Conference on the treatment of chronic hepatitis B and C in HIV co-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.5.811

A randomized trial of interferon alpha therapy for HIV type 1 infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.5.811

Care of patients with chronic hepatitis C and HIV co-infection: recommendations from the HIV-HCV International Panel.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.5.811

Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.5.811

Value of two noninvasive methods to detect progression of fibrosis among HCV carriers with normal aminotransferases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.5.811

Efficacy of non-invasive elastometry on staging of hepatic fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.5.811

Prediction of liver fibrosis in human immunodeficiency virus/hepatitis C virus coinfected patients by simple non-invasive indexes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.5.811

HIV infection does not affect the performance of noninvasive markers of fibrosis for the diagnosis of hepatitis C virus-related liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.5.811

Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.5.811

Adherence and mental side effects during hepatitis C treatment with interferon alfa and ribavirin in psychiatric risk groups

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.5.811

Hepatitis C treatment for people with severe mental illness

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.5.811

Spontaneous hepatic decompensation in patients coinfected with HIV and hepatitis C virus during interferon-ribavirin combination treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.5.811

Risk factors for hepatic decompensation in patients with HIV/HCV coinfection and liver cirrhosis during interferon-based therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.5.811

Predisposition to nevirapine hypersensitivity associated with HLA-DRB1*0101 and abrogated by low CD4 T-cell counts

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.5.811

Incidence of liver injury after beginning antiretroviral therapy with efavirenz or nevirapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.5.811

Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.5.811

Hepatotoxicity of nucleoside reverse transcriptase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.5.811

Hepatocellular carcinoma in HIV-infected patients: epidemiological features, clinical presentation and outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.5.811

HIV and hepatitis C virus co-infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.5.811

Orthotopic liver transplantation in human immunodeficiency virus (HIV)-positive patients: outcome of 7 patients from the Bonn cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.5.811

Orthotopic liver transplantation in patients with human immunodeficiency virus and end-stage liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.5.811

The interaction between antiretroviral agents and tacrolimus in liver and kidney transplant patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.5.811

Tacrolimus and lopinavir/ritonavir interaction in liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.5.811

Management of drug-to-drug interactions between cyclosporine A and the protease-inhibitor lopinavir/ritonavir in liver-transplanted HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.5.811

Peginterferon alfa-2a for hepatitis C after liver transplantation: two randomized, controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.5.811

Combined treatment with pegylated interferon (alpha-2b) and ribavirin in the acute phase of hepatitis C virus recurrence after liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.5.811

Treatment of recurrent hepatitis C after liver transplantation: a pilot study of peginterferon alfa-2b and ribavirin combination

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.5.811

Treatment of recurrent hepatitis C infection after liver transplantation with combination of pegylated interferon alpha2b and ribavirin: an open-label series.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.5.811

Pegylated interferon alpha-2b plus ribavirin in the treatment of post-liver transplant recurrent hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.5.811

Epidemiology of hepatitis C

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.5.811

Acute hepatitis C: high rate of both spontaneous and treatment-induced viral clearance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.5.811

Spontaneous resolution of chronic hepatitis C virus disease after withdrawal of immunosuppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.5.811

Transmission of hepatitis C virus among HIV-positive homosexual men and response to a 24-week course of pegylated interferon and ribavirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.5.811

Clinical presentation and course of acute hepatitis C infection in HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.5.811

Treatment of acute hepatitis C with interferon alfa-2b

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.5.811

Treatment of acute hepatitis C infection in HIV-infected patients: a retrospective analysis of eleven cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.5.811

Hepatic steatosis in HIV–HCV coinfected patients: analysis of risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2.5.811

21 January 2018

Identifiers

DOI

10.1586/1744666X.2.5.811

1 reference

21 June 2017

1 reference